Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07207369 · ClinicalTrials.gov registry record · Phase 3

A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

A Phase 3 study of Acne Scars, sponsored by AbbVie.

Recruiting
Registry status
Phase 3
Development phase
395
Enrollment target
10
Study locations

NCT07207369 is a Phase 3 study of Acne Scars that is actively recruiting participants, run by AbbVie. The registered enrollment target is 395 participants, above the 20-participant average among 6 other Acne Scars trials with a reported enrollment target (1875% higher). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07207369, a Phase 3 study of Acne Scars, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 3
Development phase
395 participants
Enrollment target
10
Study locations

Study Summary

Atrophic acne scars are flat, indented or with an inverted center scars that develop at the endpoint of the normal healing process for acne. Acne scarring that remains after acne resolves has a significant impact on health related quality of life, including reduced self-esteem and embarrassment/self consciousness. ELAPR002f provides an immediate space-occupying effect for filling in the scar tissue. The purpose of this study is to assess how safe and effective ELAPR002f injectable gel is on adult participants with atrophic acne scars. ELAPR002f injectable gel is an investigational device being developed for the treatment of facial atrophic acne scars. There are 2 cohorts in this study. In Cohort 1, all participants will receive ELAPR002f injectable gel. In Cohort 2, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to the saline active control group. Around 395 adult participants with moderate to severe atrophic acne scarring on both cheeks will be screened in the study in approximately 25 sites in the United States. Participants will receive 3 treatments over 2 months of intradermal injections of either ELAPR002f injectable gel or saline active control and will be followed for up to an additional 12 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions Studied

Acne Scars

Interventions

  • DEVICE ELAPR002f Injectable Gel
  • DEVICE Saline Control

Study Locations (10)

California

  • Marcus Facial Plastic Surgery /ID# 275880 - Redondo Beach
  • Pacific Clinical Innovations /ID# 256185 - Vista

Arizona

  • Advanced Research Associates - Glendale /ID# 254961 - Glendale

Connecticut

  • DMR Research PLLC /ID# 256199 - Westport

Georgia

  • Hamilton Research, LLC /ID# 256925 - Alpharetta

Maryland

  • Aesthetic Center at Woodholme /ID# 256197 - Baltimore

New York

  • The Center for Dermatology Cosmetics & Laser Surgery /ID# 256182 - Mount Kisco

North Carolina

  • Wilmington Dermatology Center /ID# 256192 - Wilmington

Texas

  • Austin Institute for Clinical Research - Pflugerville /ID# 256200 - Pflugerville

Trial Details

FieldValue
Enrollment Target 395 participants
Start Date 2025-10-24
Est. Completion 2029-11
Phase Phase 3

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07207369

The ClinicalTrials.gov registry entry for NCT07207369 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 395 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 20-participant average among 6 other Acne Scars trials with a reported enrollment target (1875% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne Scars appearing as the primary indexed condition, and to 2 interventions - of which ELAPR002f Injectable Gel is the first listed.

NCT07207369 reports 10 study locations spanning 9 distinct geographic areas - top geographies include California, Arizona, Connecticut.

Frequently Asked Questions

What is clinical trial NCT07207369 about?

NCT07207369 is a clinical study titled "A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars". Atrophic acne scars are flat, indented or with an inverted center scars that develop at the endpoint of the normal healing process for acne. Acne scarring that remains after acne resolves has a significant impact on health related quality of life, including reduced self-esteem and embarrassment/self...

What is the current status of trial NCT07207369?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 395 participants. The study started on 2025-10-24. Estimated completion is 2029-11.

What conditions does trial NCT07207369 study?

This clinical trial studies the following conditions: Acne Scars.

What interventions are being tested in trial NCT07207369?

The interventions under investigation include: ELAPR002f Injectable Gel (DEVICE), Saline Control (DEVICE).

Who is sponsoring clinical trial NCT07207369?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07207369 being conducted?

This trial has 10 study locations across Arizona, California, Connecticut, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acne Scars

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acne Scars

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.